DMT-2'-O-Me-G(iBu)-CE Phosphoramidite

N2-isobutyryl-5'-O-(4, 4'-Dimethoxytrityl)-2'-O-methyl-Guanosine-3'-CE-Phosphoramidite
Catalog No. PR2-002
CAS No. 150780-67-9
Purity HPLC≥98.0%
Molecular Formula C45H56N7O9P
Molecular Weight 869.94
Storage Condition -20℃

DMT-2'-O-Me-G(iBu)-CE Phosphoramidite

N2-isobutyryl-5'-O-(4, 4'-Dimethoxytrityl)-2'-O-methyl-Guanosine-3'-CE-Phosphoramidite
Grade
Amount/Package: 0.25g / 30mL screwed bottle-28
SKU: PR2-002-025A  |  suitable for  MerMade
Collections:  2'-O-Me Phosphoramidites Diagnostics Oligo Synthesis Phosphoramidites Phosphoramidites for Diagnostics Recommended Products Synthesis Blocks
Unit price:
$19.00

Price

$19.00
Shipping calculated at checkout.
This variant is unavailable. Contact us if you have particular requirements.
Checkout

This variant only support customization. Click the Inquiry button below to submit your custom request to us.

Price/Order Inquiry

Shipping notes
Products on this site:
Currently ship to United States & Canada.
For shipping worldwide, please contact us.
Processment: within 2 business days, if available.
US: 2-8 days (from CA by FedEx).
Canada: 5-10 days (excludes customs delays).

Related Products

Details

DMT-2'-O-Me-G(iBu)-CE Phosphoramidite is a 2'-OMe phosphoramidite monomer used for solid-phase oligonucleotide synthesis. It contains a 5'-dimethoxytrityl (DMT) protecting group for 5'-hydroxyl protection, a isobutyryl (iBu) base-protecting group on guanine, a cyanoethyl (CE) protecting group on phosphite, and a 2'-O-methyl (2'-OMe) ribose modification

The 2'-OMe modification improves duplex stability, reduces immunogenicity, and significantly increases resistance to nucleases

Applications

siRNA chemical modification

Applied on siRNA duplexes to improve serum stability, reduce off-target effects, and modulate RISC loading.[1][2]

Enzyme or structural RNA inhibition

Inhibit specific RNAs or enzymes (e.g., telomerase) through binding interference.[4]

Features and Benefits

Delivers high coupling efficiency and consistently strong crude yields
Manufactured to ≥98% purity with tightly controlled impurity specifications
Compatible with standard phosphoramidites under routine solid-phase synthesis conditions
Simplified purification: no special precautions needed against RNase degradation

Other Notes

  • Storage: Store in a dry, inert atmosphere at -20 °C.
  • Coupling: 6 minute coupling time recommended
  • Recommended deprotection: 8 h at 55 °C in concentrated ammonia, or 10 min at 65 °C in AMA (ammonia/methylamine, 1:1 v/v)
  • Compatibility: Can be used alongside modified phosphoramidites (e.g., 2′-OMe, 2′-MOE, Locked-NA) to synthesize chimeric oligonucleotides.

Reference

[1] Chiu, Ya-Lin, and Tariq M. Rana. "siRNA function in RNAi: a chemical modification analysis." Rna 9, no. 9 (2003): 1034-1048. [2] Hu, Bo, Liping Zhong, Yuhua Weng, Ling Peng, Yuanyu Huang, Yongxiang Zhao, and Xing-Jie Liang. "Therapeutic siRNA: state of the art." Signal transduction and targeted therapy 5, no. 1 (2020): 101. [3] Burmeister, P.E., Lewis, S.D., Silva, R.F., Preiss, J.R., Horwitz, L.R., Pendergrast, P.S., McCauley, T.G., Kurz, J.C., Epstein, D.M., Wilson, C. and Keefe, A.D., 2005. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chemistry & biology, 12(1), pp.25-33. [4] Pitts, Anne E., and David R. Corey. "Inhibition of human telomerase by 2′-O-methyl-RNA." Proceedings of the National Academy of Sciences 95, no. 20 (1998): 11549-11554.

Specifications
  • Catalog No.
    PR2-002
  • CAS No.
    150780-67-9
  • SMILES
    CC(C)N(C(C)C)P(OCCC#N)O[C@H]1[C@@H](OC)[C@H](N(C=N2)C3=C2C(NC(NC(C(C)C)=O)=N3)=O)O[C@@H]1COC(C4=CC=C(OC)C=C4)(C5=CC=CC=C5)C6=CC=C(OC)C=C6
  • Molecular Formula
    C45H56N7O9P
  • Molecular Weight
    869.94
  • Appearance
    White powder
  • Purity
    HPLC≥98.0%
  • Storage Condition
    -20℃
  • Moisture Content
    K.F.≤0.20% w/w

Documentation
COA Contact Us

DMT-2'-O-Me-G(iBu)-CE Phosphoramidite is a 2'-OMe phosphoramidite monomer used for solid-phase oligonucleotide synthesis. It contains a 5'-dimethoxytrityl (DMT) protecting group for 5'-hydroxyl protection, a isobutyryl (iBu) base-protecting group on guanine, a cyanoethyl (CE) protecting group on phosphite, and a 2'-O-methyl (2'-OMe) ribose modification

The 2'-OMe modification improves duplex stability, reduces immunogenicity, and significantly increases resistance to nucleases

Applications

siRNA chemical modification

Applied on siRNA duplexes to improve serum stability, reduce off-target effects, and modulate RISC loading.[1][2]

Enzyme or structural RNA inhibition

Inhibit specific RNAs or enzymes (e.g., telomerase) through binding interference.[4]

Features and Benefits

Delivers high coupling efficiency and consistently strong crude yields
Manufactured to ≥98% purity with tightly controlled impurity specifications
Compatible with standard phosphoramidites under routine solid-phase synthesis conditions
Simplified purification: no special precautions needed against RNase degradation

Other Notes

  • Storage: Store in a dry, inert atmosphere at -20 °C.
  • Coupling: 6 minute coupling time recommended
  • Recommended deprotection: 8 h at 55 °C in concentrated ammonia, or 10 min at 65 °C in AMA (ammonia/methylamine, 1:1 v/v)
  • Compatibility: Can be used alongside modified phosphoramidites (e.g., 2′-OMe, 2′-MOE, Locked-NA) to synthesize chimeric oligonucleotides.

Reference

[1] Chiu, Ya-Lin, and Tariq M. Rana. "siRNA function in RNAi: a chemical modification analysis." Rna 9, no. 9 (2003): 1034-1048. [2] Hu, Bo, Liping Zhong, Yuhua Weng, Ling Peng, Yuanyu Huang, Yongxiang Zhao, and Xing-Jie Liang. "Therapeutic siRNA: state of the art." Signal transduction and targeted therapy 5, no. 1 (2020): 101. [3] Burmeister, P.E., Lewis, S.D., Silva, R.F., Preiss, J.R., Horwitz, L.R., Pendergrast, P.S., McCauley, T.G., Kurz, J.C., Epstein, D.M., Wilson, C. and Keefe, A.D., 2005. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chemistry & biology, 12(1), pp.25-33. [4] Pitts, Anne E., and David R. Corey. "Inhibition of human telomerase by 2′-O-methyl-RNA." Proceedings of the National Academy of Sciences 95, no. 20 (1998): 11549-11554.

Why choose Hongene?

Trusted Partner in Nucleic Acid

Integrated Supply & Commercial Scale

With 26+ years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.

Proprietary Technology & IP

Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.

Rigorous Quality

We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.

Manufacturing Scalability

Hongene operates 1.67 million sq. ft Oligonucleotide Manufacturing Facility, with advanced equipments including multiple OligoPilot™ and OligoProcess™ synthesizers (10-1800 mmol). 48 flexible production lines enable one-stop seamless scaling-up of API production from gram-level to tons and acheive high purity of 98%, meeting NMPA, FDA, and EMA standards.

Global Business Network

Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.

Global Business Distribution
40+
Countries & Regions
3000≈
Global Clients
54000+L
Annual NTP Production
58+t
Annual Amidites Production

Ask us anything!

Back to top

My Wishlist